Key Details
Price
$33.90Annual ROE
-9.67%Beta
0.22Events Calendar
Next earnings date:
May 1, 2025Recent quarterly earnings:
Jan 30, 2025Recent annual earnings:
Nov 8, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 7, 2000Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
FAQ
- What is the ticker symbol for Surmodics?
- Does Surmodics pay dividends?
- What sector is Surmodics in?
- What industry is Surmodics in?
- What country is Surmodics based in?
- When did Surmodics go public?
- Is Surmodics in the S&P 500?
- Is Surmodics in the NASDAQ 100?
- Is Surmodics in the Dow Jones?
- When was Surmodics's last earnings report?
- When does Surmodics report earnings?
- Should I buy Surmodics stock now?